- Tafamidis for Cardiac Transthyretin Amyloidosis
-
Darae Kim, Jin-Oh Choi, Eun-Seok Jeon
-
Cardiovasc Prev Pharmacother. 2021;3(1):1-9. Published online January 31, 2021
-
DOI: https://doi.org/10.36011/cpp.2021.3.e1
-
-
32,500
View
-
88
Download
-
2
Citations
-
 Abstract
 PDF
- Transthyretin amyloid (ATTR) cardiomyopathy is a progressive disease caused by the infiltration of ATTR fibrils in the myocardium. Although it is a rare disease, ATTR cardiomyopathy is an important cause of heart failure with preserved ejection fraction, and its incidence is increasing due to improved diagnostic imaging tools. There has been a breakthrough in the field of transthyretin amyloidosis, which opens a new therapeutic door for the patients. In this review, an overview of tafamidis therapy in ATTR cardiomyopathy with recent results from clinical trials will be discussed.
-
Citations
Citations to this article as recorded by  - A Comprehensive Review on Chemistry and Biology of Tafamidis in
Transthyretin Amyloidosis
Monali B. Patil, Piyush Ghode, Prashant Joshi
Mini-Reviews in Medicinal Chemistry.2024; 24(6): 571. CrossRef - Multimodal Imaging and Biomarkers in Cardiac Amyloidosis
Mi-Hyang Jung, Suyon Chang, Eun Ji Han, Jong-Chan Youn
Diagnostics.2022; 12(3): 627. CrossRef
|
